Aberdeen Group plc Has $12.92 Million Stock Position in Tempus AI, Inc. $TEM

Aberdeen Group plc decreased its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 24.9% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 160,126 shares of the company’s stock after selling 53,168 shares during the period. Aberdeen Group plc owned 0.09% of Tempus AI worth $12,924,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC bought a new stake in shares of Tempus AI in the second quarter valued at about $54,020,000. Geode Capital Management LLC lifted its holdings in Tempus AI by 411.4% during the 2nd quarter. Geode Capital Management LLC now owns 649,420 shares of the company’s stock valued at $41,264,000 after purchasing an additional 522,443 shares during the last quarter. Marex Group plc bought a new position in shares of Tempus AI in the second quarter valued at approximately $26,620,000. Gilder Gagnon Howe & Co. LLC boosted its stake in Tempus AI by 1,747.6% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 413,081 shares of the company’s stock worth $26,247,000 after purchasing an additional 390,723 shares in the last quarter. Finally, Patient Capital Management LLC acquired a new position in Tempus AI during the 2nd quarter worth about $24,693,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on TEM shares. JPMorgan Chase & Co. decreased their price objective on Tempus AI from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. BTIG Research increased their target price on shares of Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Canaccord Genuity Group reduced their target price on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, December 22nd. Finally, Mizuho began coverage on shares of Tempus AI in a research note on Thursday. They set an “outperform” rating and a $100.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Tempus AI presently has an average rating of “Hold” and an average price target of $85.92.

Insider Activity

In other Tempus AI news, CFO James William Rogers sold 19,966 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $73.20, for a total value of $1,461,511.20. Following the sale, the chief financial officer owned 111,250 shares in the company, valued at approximately $8,143,500. The trade was a 15.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Erik Phelps sold 1,302 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $67.42, for a total transaction of $87,780.84. Following the sale, the executive vice president directly owned 89,280 shares of the company’s stock, valued at $6,019,257.60. This represents a 1.44% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 544,188 shares of company stock valued at $37,163,496. Corporate insiders own 26.27% of the company’s stock.

Tempus AI Price Performance

TEM stock opened at $59.96 on Friday. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. Tempus AI, Inc. has a 12 month low of $36.22 and a 12 month high of $104.32. The firm has a market cap of $10.67 billion, a P/E ratio of -50.39 and a beta of 5.22. The company’s 50-day moving average price is $62.60 and its two-hundred day moving average price is $73.38.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus announced a new pan‑cancer HRD‑RNA algorithm for homologous recombination deficiency detection — a clinical/ product milestone that investors see as expanding Tempus’s diagnostic addressable market and commercialization runway. Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm
• Positive Sentiment: Market headlines note the stock rise after the algorithm launch, framing the update as momentum into earnings — a near‑term sentiment catalyst. Tempus AI stock rises after launching new cancer detection algorithm
• Positive Sentiment: Coverage (247WallSt/Yahoo syndication) highlights the algorithm as the reason shares are climbing and points to the upcoming Q4 report as the next major catalyst. Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings
• Positive Sentiment: Yahoo Finance and other outlets explain the same narrative: product news + pre‑earnings positioning has lifted sentiment — but note they also list items investors should watch before earnings. Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings
• Positive Sentiment: General consumer/press Q&A pieces summarize the move and point investors to upcoming earnings and product commercialization as the primary drivers. What’s going on with Tempus AI stock today?
• Neutral Sentiment: Zacks digs into Wall Street estimates for Q4 key metrics, offering deeper model inputs investors can use to set expectations for the Feb. 24 report. Unlocking Q4 Potential of Tempus (TEM): Exploring Wall Street Estimates for Key Metrics
• Neutral Sentiment: Another Zacks piece weighs TEM’s expected ~82.8% revenue growth vs. premium valuation — useful context but highlights the tradeoff between growth and valuation risk into earnings. Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?
• Neutral Sentiment: Forbes examines the valuation question at ~$60 — notes TEM trades at a premium on traditional metrics and remains GAAP‑unprofitable, but discusses why growth/analyst optimism may still justify interest. Is TEM Stock A Buy At $60?
• Neutral Sentiment: Robert W. Baird initiated coverage with an “outperform” and $59 PT — the initiation adds legitimacy but the price target is roughly in line with current levels, signaling limited near‑term upside per that call. Baird initiation article
• Neutral Sentiment: Analysis pieces reassessing valuation after recent weakness highlight the gap between analyst targets and market price; these are reminders that downside exists if growth disappoints. Assessing Tempus AI (TEM) Valuation After Recent Share Price Weakness And Analyst Target Gap
• Neutral Sentiment: Market roundup pieces include TEM in broader market context; useful for macro risk but not company‑specific news. Stock Market Live February 17, 2026

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.